Abstract Aromatase inhibitors (AIs) are important drugs for treating postmenopausal patients with hormone receptor-positive breast cancer. However, acquired resistance to AI therapies is a significant problem. Our study has revealed that the histone deacetylase inhibitor LBH589 treatment abrogated growth of AI-resistant cells in vitro and in vivo, causing cell cycle G2/M arrest and induced apoptosis. LBH589 treatment also reduced the level of NF-jB1 which is overexpressed when AI resistance develops. Analyzing paired tumor specimens from 12 patients, we found that NF-jB1 expression was increased in recurrent AI-resistant tumors as compared to the paired primary tumors before AI treatment. This finding was consistent with up-regulated NF-jB1 expression seen in a collection of well-established AI-resistant cell lines. Furthermore, knockdown of NF-jB1 expression significantly suppressed the proliferation of AI-resistant cells. Treatment of AI-resistant cell lines with LBH589 suppressed NF-jB1 mRNA and protein expression. In addition, LBH589 treatment abrogated growth of AI-resistant tumors in mice, and was associated with significantly decreased levels of NF-jB1 in tumors. In all, our findings strongly support further investigation of LBH589 as a novel therapeutic strategy for patients with AI-resistant breast cancer, in part by suppressing the NF-jB1 pathway.
Introduction
Since the third-generation aromatase inhibitors (AIs) (i.e., anastrozole, letrozole, and exemestane) have been shown to be more effective in prolonging disease-free survival than tamoxifen [1] , these AIs are now the first choice of endocrine therapy as initial adjuvant therapy or for metastatic disease instead of tamoxifen, especially for postmenopausal patients with hormone receptor (HR)-positive breast cancer. Unfortunately, *20-25 % of patients will eventually develop resistance to AIs within a decade after adjuvant Makoto Kubo and Noriko Kanaya contributed equally to this study.
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The online version of this article (doi:10.1007/s10549-012-2332-x) contains supplementary material, which is available to authorized users. treatment [2] [3] [4] . Furthermore, most of the patients with metastatic disease develop resistance to AIs around 9-10 months. Thus, acquired AI resistance is a major problem in the management of HR-positive breast cancer, and it is critical to find new strategies to treat acquired AI resistance.
The mechanisms of acquired AI resistance are poorly understood. There are two main reasons for insufficient progress in this area. The research has been delayed due to the lack of suitable preclinical models. A significant number of experiments to study AI resistance have been performed using models without the presence of aromatase and estrogen receptor (ER), i.e., non-physiologically relevant models. Our laboratories have prepared ER-and aromatase-positive breast cancer cell lines (i.e., MCF-7aro and T47Daro) and generated a series of acquired AI, as well as tamoxifenresistant cell lines [5] . These cell lines allow us to evaluate the molecular differences between AI and tamoxifen resistance in a simultaneous manner [6] , and to identify essential players involved in acquired AI resistance. Another difficulty to study acquired AI resistance is the shortage of paired tumor tissues from the same patients before AI treatment and after cancer recurrence for confirming the findings from preclinical studies. The lack of these paired samples is due to unpredictability of patients to acquire AI resistance, and surgery not being the typical option when cancer recurs.
Using our models, we have found that LBH589 (panobinostat), a histone deacetylase (HDAC) inhibitor, is a potentially effective drug to treat acquired AI resistance. HDACs are enzymes involved in the remodeling of chromatin and have a key role in the epigenetic regulation of gene expression [7] . Small-molecule HDAC inhibitors can function as anticancer drugs to suppress a variety of HDAC-regulated activities including apoptosis, cell cycle arrest in G2/M phase and cell differentiation [8] . LBH589 is a novel cinnamic hydroxamic acid analog HDAC inhibitor. It has been evaluated through phase I/II clinical trials on multiple myeloma, and hematological and solid tumors [9] .
In this article, we will also present results to support nuclear factor-jB1 (NF-jB1) as an important target of LBH589 and its important role in acquired AI resistance through studies using our AI-resistant cell models and analyzes of a collection of paired clinical specimens from the same patients before AI treatment and after cancer recurrence following AI treatment. Several studies indicate that NF-jB is activated in breast cancer cells where it enhances cell proliferation and suppresses apoptosis [10] . The Rel or NF-jB family can form hetero-or homodimeric combination of five members: NF-jB1 (p50 and its precursor p105), NF-jB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel. Activation of the classic NFjB complex, composed of NF-jB1/RelA heterodimers, is detected in a portion of breast cancers [11] . Furthermore, several studies have demonstrated that some HDAC inhibitors suppress NF-jB pathway signaling [12, 13] . Moreover, DNA microarray profiling of colon cancer cells treated with the HDAC inhibitors vorinostat and LBH589 revealed that this treatment caused significant down-regulation of NF-jB1 expression [14] . Therefore, down-regulation of NF-jB1 is thought to be one mechanism by which HDAC inhibitors induce apoptotic effects in cancer cells.
Our data in this article support further evaluation of LBH589 as a new therapeutic option for AI-resistant breast cancer. In addition, our results indicate that NF-jB1 is potentially an important gene involved in AI resistance and a marker of LBH589-mediated inhibition.
Materials and methods

Cell culture and reagents
The ER-positive aromatase-overexpressing MCF-7 and T47D cell lines, MCF-7aro and T47Daro, respectively, were generated in our laboratory as previously described [15] . We also used AI-resistant cell lines derived from MCF-7aro which are resistant to anastrozole (Ana-R), letrozole (Let-R) or exemestane (Exe-R), as well as a longterm estrogen-deprived MCF-7aro line (LTEDaro) [6, 16] . A long-term estrogen-deprived T47Daro (T47DaroLTED) cell line was recently generated and also used. T47Da-roLTED cells were cultured in RPMI-1640, without phenol red, and supplemented with 10 % charcoal-dextran-treated FBS. LBH589 was provided by Novartis Pharmaceutical Inc. TNF-a was purchased from R&D Systems.
Cell proliferation assay, western blotting, and cell cycle analysis Please see supplementary materials for procedures.
Animal studies Female, 6-to 7-week-old ovariectomized, BALB/c Nu-Nu athymic mice were purchased from the National Cancer Institute and housed/maintained on a 12 h light/dark cycle in the City of Hope Animal Facility. All animal research procedures were approved by the City of Hope Institutional Animal Care and Use Committee. The design of the animal studies are shown in Fig. 3a . At 8 weeks of age, mice were s.c. injected in the hind flank with MCF7aro cells (2 9 10 7 cells/injection site) mixed with an equal volume of Matrigel (BD Bioscience). Mice were also s.c. implanted with 7.5 mg/60 days time-release androstenedione pellets (Innovative Research of America). Tumor size and body weights were monitored three times per week as an indicator of overall health. All mice received food and water ad libitum. To establish the exemestane-resistant xenograft, mice were s.c injected daily with exemestane (250 lg/mouse) when tumors became 400 mm 3 . Tumors responded to exemestane treatment initially; however, they eventually became resistant in several weeks. When resistant tumors reached 700 mm 3 , mice were randomly divided into two groups of 7 mice each, then treated with exemestane only (daily) or exemestane (daily) and LBH589 (20 mg/kg, three times per week, intraperitoneally), as a design to evaluate the effect of a new drug (i.e., LBH589) together with an established drug (i.e., exemestane). After 3 weeks of LBH589 treatment, mice were euthanized via CO 2 asphyxiation. Tumors were removed, weighted and sent for H&E histologic staining through the City of Hope Pathology Core Facility (Please see supplementary materials for procedures for detail methods).
Real-time PCR analysis
Please see supplementary materials for procedures.
Microarray analysis, statistical processing and Ingenuity Pathway Analysis (IPA) Please see supplementary materials for procedures.
Clinical samples
Three hospitals (Kumamoto City Hospital, Hamanomachi Hospital, and Hokkaido Cancer Center) and one clinic (Shimada Breast & Surgery Clinic) were involved in enrolling the subset of 12 patients with primary breast tumors who developed recurrent tumors following AI therapy. All patients gave informed consent and the study was approved by the appropriate institutional review boards. Patient characteristics are shown in Table 1 . For immunohistochemical analysis, the tumor specimen slides (3-4 lm) were stained using NF-jB1 antibody (H-119, Santa Cruz Biotechnology) (Please see supplementary materials for procedures for detail methods).
Luciferase assay, NF-jB1 siRNA treatment and NF-jB1 transfection Please see supplementary materials for procedures.
Statistics
To assess statistical significance, values were compared with controls by either Student's t test or one-way ANOVA, followed by Dunnett's multiple range test (a = 0.05) using Prism GraphPad 5 software (GraphPad Software, Inc.).
Results
LBH589 inhibits the proliferation of AI resistant breast cancer cells
To study cellular response to AIs and the mechanisms of acquired AI resistance, we used the previously generated AI-responsive cell line MCF-7aro [15] and AI-resistant variants of MCF-7aro created following in vitro selection against each AI (i.e., Exe-R, Let-R, and Ana-R) or longterm culture in the absence of estrogen (i.e., LTEDaro) [16] . Our molecular characterization has implicated LTEDaro as a model of late-stage AI resistance as it fails to respond to any of the three AIs [16] . MCF-7aro, LTEDaro and three AI-resistant cell lines were exposed to increasing concentrations of LBH589. This druginhibited proliferation of all cell lines in a dose-dependent manner (Fig. 1a) . To confirm the effect of LBH589, we used another ER-positive aromatase-overexpressing cell line, T47Daro [15] which was derived from T47D, and T47Da-roLTED which is long-term estrogen-deprived T47Daro. T47Daro proliferates in response to testosterone and estrogen treatment and T47DaroLTED proliferates without the need of testosterone or estrogen (Fig. 1c) . The proliferation of T47Daro was inhibited by letrozole treatment, while T47DaroLTED cells were resistant to letrozole treatment ( Fig. 1d ). Similar to its effect on AI-resistant MCF-7aro cell lines, LBH589 effectively suppressed growth of both AIresponsive T47Daro and AI-resistant T47DaroLTED cells in a dose-dependent manner (Fig. 1b) .
LBH589 induces apoptosis and cell cycle arrest in AI resistant cell lines
Western blotting analysis further demonstrated that LBH589 treatment-induced expression of apoptosis-associated proteins, as indicated by elevated levels of cleaved poly (ADP-ribose) polymerase (cleaved PARP, a hallmark of apoptosis) and the pro-apoptotic protein Bax, as well as by reduced levels of the pro-survival protein Bcl-xL, and this induction was dose dependent (Fig. 2a) . In addition, levels of p21 WAF1/CIP1 were enhanced by LBH589 treatment; thus, confirming that LBH589 inhibits cell cycle progression.
To confirm LBH589-induced apoptosis, flow cytometry was applied to examine the effects of LBH589 treatment on the cell cycle distribution of MCF-7aro and Exe-R cells. Both cell lines displayed a significant G2/M arrest accompanied by a sharp reduction in cells in the G1 and S phases after treatment with LBH589 (Fig. 2b) ; the percentage of cells in S phase decreased from 18.0 % in untreated controls to 2.6 % for MCF-7aro and from 9.5 to 1.6 % for Exe-R. 
LBH589 inhibits the Exe-R tumor growth in vivo
To evaluate the inhibitory effects of LBH589 on AI resistance in vivo, we used the exemestane-resistant MCF7aro xenograft model (described in ''Materials and methods'') ( Fig. 3a) . Initially, to confirm the biochemical effect of LBH589 in vivo, four mice from both exemestane alone and exemestane ? LBH589 groups were sacrificed 48 h after the first injection of LBH589. The remaining mice (7 mice per group) were treated for 22 days. LBH589 treatment significantly inhibited the growth of exemestaneresistant tumors; tumor weight at the end of experiment was significantly lesser in mice treated with LBH589 than in control mice (Fig. 3b) . No mice in the LBH589 treatment groups showed significant body weight loss ( Fig. 3c ),
indicating that the LBH589 treatment was well tolerated. Consistent with the effect of LBH589 on gross characteristics of the tumors, proliferation (assessed by Ki-67 staining) of tumor cells was significantly decreased in LBH589-treated mice and apoptosis (assessed by staining for cleaved PARP) of tumor cells was significantly increased (Fig. 3d ).
Identification of differentially expressed genes in LBH589-treated cells
To identify the effective targets of LBH589 treatment, as a nonbiased approach, we compared gene expression profiles of three types of human cancer cell lines (H295R, HeLa and MCF-7her2) with and without LBH589 treatment (50 nM, 24 h). We compared the LBH589-modulated genes identified from these cell lines and analyzed their functional grouping by IPA. These microarray datasets contain probes for 20,140 unique genes of which 335 were down-regulated in all three cell lines after treatment with LBH589 (Fig. 4a) . The IPA networks of those genes most consistently down-regulated by LBH589 were enriched for genes associated with cell death, cellular function and maintenance, and the cell cycle. In particular, the most down-regulated network (Fig. 4b) valuable because they are truly paired tissues from the same patients before and after they acquired AI resistance, allowing for a direct comparison of molecular features associated with changes of the response to AIs. Tumor specimens were stained using NF-jB1 antibody to detect nuclear NF-jB1 protein levels as an activation marker (Fig. 5a ). The nuclear staining scores of 9/12 samples were significantly higher in recurrent tumor cells in comparison with those of paired primary tumor cells (Wilcoxon matched pairs signed rank test; p = 0.0248, n = 12), two were not changed and one decreased (Fig. 5b) .
NF-jB1 expression is constitutively up-regulated and NF-jB activity is increased in AI-resistant cells
We found that AI-resistant cells exhibited higher levels of NF-jB1 mRNA compared with AI-responsive MCF-7aro cells ( Fig. 6a ; p \ 0.01). Expression of the RelA and NF-jB2 subunits did not differ between AI-responsive and AI-resistant cell lines (data not shown). The levels of NFjB1 and p-NF-jB1 were also examined by western blot analysis. While the results indicate that the levels of p-NFjB1 were higher in AI-resistant cells, to demonstrate higher transcriptional activity of NF-jB in resistant cells, we performed a luciferase reporter assay in which MCF-7aro and AI-resistant cells were co-transfected with a p-NF-jB-luciferase reporter plasmid or a mock control. The NF-jB promoter activity was tenfold greater (p \ 0.01) in AI-resistant cells compared with the AI-sensitive MCF-7aro cells (Fig. 6b) . Moreover, the transcriptional activity of NF-jB was remarkably elevated after 1-h treatment with TNF-a (10 ng/ml), especially in AI-resistant cells such as LTEDaro and Exe-R.
NF-jB1 knockdown suppresses the proliferation of AIresistant cells
To confirm the functional significance of NF-jB1, we transfected MCF-7aro, LTEDaro and three AI-resistant cell lines with siRNA against NF-jB1. As the expression of NF-jB1 was effectively suppressed by siRNA in all cell lines ( Supplementary Fig. 1 ), siRNA treatment significantly suppressed the proliferation of LTEDaro and three AI-resistant cell lines, as assessed by MTT assay, but proliferation of MCF-7aro was less affected (Fig. 6c) . These data suggest that NF-jB1 plays a more indispensable role in AI-resistant cells than in AI-responsive cells such as MCF-7aro. Fig. 6 Overexpression of NF-jB1-induced AI resistance and plays an important role for cell proliferation. a Basal NF-jB1 mRNA and protein expressions were shown in AI-responsive MCF-7aro cells and AIresistant cells. mRNA levels were determined by real-time PCR. *p \ 0.01. Protein levels were evaluated by western blotting using indicated antibodies against NF-jB1 and p-NF-jB1. b The basal transcriptional activity of NF-jB is higher in AI-resistant cells (LTEDaro and Exe-R) than MCF-7aro, and remarkably higher after TNF-a (10 ng/ml) stimulation for an hour. NF-jB activity was evaluated via the p-NF-jB-luciferase reporter assay. Luciferase activity was assayed after 24 h and normalized to total protein concentration. Data are expressed as relative luciferase units (RLU). 
NF-jB1 overexpression induces AI resistance
To confirm that overexpression of NF-jB1 induces AI resistance, we assessed the response of NF-jB1-overexpressing MCF-7aro cells to letrozole. Real-time PCR analysis confirmed that NF-jB1 expression was higher in cells transfected with the NF-jB1 plasmid versus mock transfected cells (Fig. 6d) . MCF-7aro cells transfected with an NF-jB1 overexpression plasmid were significantly less responsive to letrozole (50 and 100 nM) treatment as
shown by an increase in cell proliferation relative to mock transfected cells (Fig. 6e) . Taken together, these results strongly confirm an essential role of NF-jB1 in acquisition of AI resistance.
LBH589 reduces NF-jB1 expression in breast cancer NF-jB1 expression was significantly reduced in all five cell lines after treatment with LBH589 (Fig. 7a) . Also, NF-jB1 mRNA expression was analyzed by real-time PCR. Gene expression was normalized to b-actin. *p \ 0.05; **p \ 0.01. c MCF-7aro and Exe-R were treated with 20 nM LBH589 for 16 h, and total RNA was extracted at the indicated time points. Real-time PCR was used to assess expression of NF-jB1, RelA, NF-jB target genes (CFLAR and CCND1) and CDKN1A. Gene expression was normalized to b-actin mRNA. Data are expressed as a ratio of treated samples to untreated controls and shown as mean ± SE NF-jB1 expression was significantly reduced in T47Daro and T47DaroLTED cells after LBH589 treatment (Fig. 7b) . Baseline NF-jB1 expression was found to be significantly higher in T47DaroLTED cells than in AI-responsive T47Daro cells (Fig. 7b) .
LBH589 changed the expression of NF-jB1-targeted genes
Real-time PCR throughout a 16-h time course after LBH589 treatment revealed that the expression of NF-jB1-targeted genes (CFLAR and CCND1 [encoding cyclin D1]) decreased in both cell lines (Fig. 7c) . However, neither cell line showed a remarkable change in RelA expression. Expression of CDKN1A (encoding p21 WAF1/CIP1 , cyclindependent kinase inhibitor 1) increased dramatically in response to LBH589 treatment in AI-responsive cells and peaked at the 8-h treatment, however it was not seen in AI-resistant cells (Fig. 7c) .
LBH589 inhibits the Exe-R tumor growth through suppression of NF-jB1 pathway in vivo NF-jB1 mRNA expression was significantly decreased in tumors from mice treated with LBH589 at 48 h (Fig. 8a) and at the end of experiment (Fig. 8b) . To further demonstrate the inhibitory effect of LBH589 on AI resistance, we established an exemestane-resistant cell line, long-term exemestane-treated (LTET), from the above resistant tumors (Please see supplementary materials for procedures for detail methods). We confirmed the exemestane resistance of the LTET cell line by comparing it to the parental cell line MCF-7aro. Again, LBH589 was effective at suppressing the proliferation of the parental cell line MCF7aro and LTET cells in a dose-dependent manner (Fig. 8c) . Also, NF-jB1 expression was significantly higher in LTET cells than MCF-7aro cells (Fig. 8d) . These results serve as additional evidence that AI-resistant cells, derived from resistant tumors, express higher levels of NF-jB1 and are responsive to LBH589 treatment. LBH589 decreased the NF-jB1 (p50) protein and its phosphorylated form in nuclear fraction LBH589 suppressed expression of NF-jB1(p50) and reduced levels of phosphorylated NF-jB1 (p-p50), which is the form that enhances transcriptional activity of the NF-jB complex in MCF7aro and Exe-R cells treated with LBH589 in a dose-dependent manner (Fig. 9a) . Protein levels of the heat shock protein (HSP) 90 client proteins (ERa and AKT) and the NF-jB downstream molecule (cFLIP) were reduced in a dose-dependent manner (Fig. 9a) .
To gain further insight on molecular action of LBH589, we fractionated and extracted cytoplasmic and nuclear proteins. Levels of NF-jB1 (p50) and p-NF-jB1(p-p50) were decreased in both the cytoplasm and nuclear fractions after LBH589 treatment but those of RelA and p-RelA remained relatively constant (Fig. 9b) , which was consistent with the time course study of mRNA expression (Fig. 7c) . Lamin A/C, a nuclear membrane structural protein, is cleaved by caspase-6 and serves as a marker for caspase-6 activation. In addition, cleavage of lamin A/C into a large (40-45 kDa) and a small (28 kDa) fragment, results in nuclear disregulation and apoptosis. Therefore, cleaved lamin A/C is a marker of nuclear fraction and of apoptosis.
Discussion
AIs are effective in treating postmenopausal patients with ER-positive breast cancer. However, resistance to these drugs remains a major problem in the management of this cancer. In this study, we showed that LBH589-inhibited growth of AI-resistant cancer cells, both in vitro and in vivo, by inhibiting NF-jB1 expression, inducing apoptosis and cell cycle arrest. Moreover, we demonstrated enhanced NF-jB1 expression in acquired AI resistant tumor specimens and in our acquired AI resistant models, determined that NF-jB1 promotes the growth of AI-resistant cells.
Vorinostat was the first HDAC inhibitor approved by the FDA for the treatment of cancer. The combination of vorinostat and tamoxifen is well tolerated and exhibited promising activity in hormone resistant breast cancer [17] . Recently, it was reported that the HDAC inhibitor Entinostat together with exemestane significantly improved the progression-free survival of postmenopausal women with ER-positive advanced breast cancer who had B1 prior chemotherapy and had progressed on a non-steroidal AI [18] . LBH589 is a highly potent HDAC inhibitor with demonstrated antitumor activities at low nanomolar concentration in several preclinical studies and its clinical efficacy is currently under investigation in several clinical trials such as recurrent high-grade glioma and refractory Hodgkin lymphoma [19] [20] [21] . Not all HDAC inhibitors function identically; thus, it is not unexpected that some HDAC inhibitors activate [22] [23] [24] and some inhibit [12, 13, [25] [26] [27] [28] NF-jB transcription. It has been found that more genes are repressed than activated in tumor samples treated with LBH589 [29] . Our current study shows that NF-jB1 is significantly suppressed by LBH589 treatment, similar to that reported previously in colon cancer [14] .
It is essential to recognize the difficulty of collecting paired tumor tissues from the same patients before AI treatment and after the acquisition of AI resistance. We were able to collect the primary tumor specimens and those after cancer recurred from 12 patients, even after up to 6 years of treatment with AIs. We also found that the rate Protein expression changes of NF-jB1 and related molecules by LBH589 treatment. a LBH589 suppressed NF-jB1 (p50) protein expression and its phosphorylated form in a dose-dependent manner. Blots were probed with the indicated antibodies against NF-jB downstream molecules (cFLIP) and LBH589 targets (AKT and ERa). LBH589 suppresses the expression of these molecules in a dosedependent manner. Western blot analysis were performed on MCF7aro and Exe-R cells that were treated with DMSO (control) or the indicated concentrations of LBH589 for 48 h. b Levels of NF-jB1 and p-NF-jB1 were decreased in both nuclear and cytoplasmic fraction in a dose-dependent manner. Cells were fractionated into cytoplasm and nuclear fractions after treatment with DMSO or LBH589 for 48 h, and protein levels of interesting proteins in the cytoplasm and nucleus were examined by western blotting. Lamin A/C (70 kDa) was used as a nuclear marker of acquired AI resistance (6.5 %) to the adjuvant therapy in Japanese patients is lower than that in patients from Western countries. All recurrent tumors, except one (#7), remained ER-positive, supporting that ER-mediated pathways remain important in AI-resistant tumors, as suggested by our preclinical studies [6] . Although the primary tumors from two of twelve patients were HER2-positive, these patients responded to AI treatment for 18 and 58 months, respectively. Therefore, there were no obvious correlations between HER2 levels and time to recurrence. Using those samples, we have found that tumors from patients who acquired AI resistance had higher expression of NF-jB1 compared to primary tumors from the same patients before AI treatment. This is the first report to show that NF-jB1 is expressed at higher levels in acquired AI-resistant patient samples. In support of these findings, NF-jB1 is overexpressed in AI-resistant cell lines. It is worthwhile to note that the expression of NF-jB1 is not elevated in tumors after a 2-week treatment or 3-month treatment with an AI [30] , indicating that a short-term treatment of an AI does not change the expression of NF-jB1.
NF-jB forms an inducible transcription factor complex that plays a crucial role in regulating the inflammatory, immune, and anti-apoptotic reactions. Notably, the signaling pathways that lead to tamoxifen resistance share a common mechanistic link with activation of the gene-regulating NFjB complex [31] [32] [33] . The higher NF-jB1 DNA-binding values were associated with significantly reduced diseasefree survival among a collection of 81 ER-positive primary breast cancers [32] . Patients whose primary breast cancers overexpressed NF-jB1 were significantly more likely to develop distal metastases and experienced shorter metastasis-free survival than those whose cancers did not [32] . As Zhou et al. have reported the role of NF-jB1 in de novo tamoxifen resistance, we now report the functional significance of NF-jB1 in acquired AI resistance. It should be noted that RelA has been also reported to play an important role in tamoxifen resistant [31] . Activate NF-jB1 (p50) homodimer can be transcriptional repressors or activators both [34] . Our nuclear expression results showed that LBH589 could reduce expression of NF-jB1 (p50) and its phosphorated form which was promoting NF-jB1 in nuclear fraction, potentially to interact with RelA in the AI resistant cells. Our results suggested that LBH589-inhibited tumor growth through reduction of NF-jB1 (p50)/RelA dimers.
Our preclinical studies have revealed that NF-jB1 is more important in promoting the growth of AI-resistant cells than of AI-responsive cells. NF-jB1 knockdown further showed that NF-jB1 is indispensable in AI-resistant cells but less important in responsive cells. Since LBH589 suppresses the proliferation of both AI-resistant and AI-responsive cells, our data indicate that LBH589 can suppress the proliferation of ER-and aromatase-positive breast cancer through more than one mechanism. As a comparison, LBH589 is less effective in the suppression of MCF-10A, a noncancerous breast epithelial cells (supplementary Fig. 2 ). Previous studies have also indicated CDKN1A is readily up-regulated in response to HDAC inhibitor treatment in vitro [35] . CDKN1A was found to be most up-regulated at a relatively early phase (8 h) after LBH589 treatment in AI-sensitive cells, but not in AIresistant cells. Thus, cell cycle signaling via p21 WAF1/CIP1 is likely to be more sensitive to LBH589 in AI-responsive cells than AI-resistant cells. Our in vitro results indicate that LBH589 inhibits ER-positive AI-responsive cells, which is consistent with our previous finding that combination therapy of an AI and LBH589 can synergistically inhibit the proliferation of AI-responsive cells [36] . In this study, we focused on elucidating the mechanism underlying LBH589 0 s effects on AI-resistant cell lines, and showed that LBH589 inhibits the NF-jB1 pathway. After patients become AI resistant, there are no effective ways to treat them; thus, LBH589 may be a potential choice for the patients who acquire AI resistance.
LBH589 inhibits HDAC6, which has also been identified as a major deacetylase of HSP90 [37] . HSP90 is a cytoplasmic chaperone whose client proteins include nuclear receptors and kinases important for oncogenesis. HSP90 acts to prevent their ubiquitinylation and proteasomal degradation. LBH589 induces tumor cell apoptosis that HSP90 and its co-chaperones modulate through downregulation of AKT, TNF-a, and NF-jB function [38] . Also, HDAC inhibitors potentiate anti-estrogen therapy and/or lead to a reversal of hormone therapy resistance through the interaction of HDAC6 with the ER and HSP90 chaperone complex [39] . Our results further show that AKT and ER protein levels are reduced in cells treated with LBH589. It has been reported that NF-jB activity can be up-regulated by acetylation of RelA/p65 in the nucleus, which is mediated by histone acetyl transferases (e.g., P300, CBP, and PCAF) [24] . Interleukin-1 receptor-associated kinase 1 (IRAK1) is the upstream gene that stimulates the NF-jB pathway [40] . Our microarray analyzes indicated that expression of CREBBP (encoding CBP/ p300) and IRAK1 were decreased, consistent with previous reports [14] . These factors may contribute to the mechanisms by which LBH589 inhibits the NF-jB pathway.
Induced NF-jB has been reported to increase aromatase expression by enhancing transcription of several proinflammatory mediators [41, 42] and synergistically activates ER [43] . Interestingly, our previous studies have demonstrated that LBH589 can suppress aromatase expression through the down-regulation of promoters I.3 and II [36] . Thus, LBH589 can overcome AI resistance through multiple pathways. For triple negative breast cancer, it was reported that LBH589 suppressed the proliferation [44] , and moreover HDAC inhibitors increased ER expression [45, 46] , suggesting that the inhibitory mechanisms of this drug are different in ER? and ER-breast cancers.
Recent exciting clinical observations from other groups, together with our preclinical data for LBH589, strongly suggest that LBH589 offers a novel therapeutic strategy to improve the response of hormone responsive cancers to AIs and thereby overcome AI resistance.
